More on VIVS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.45 |
|
|||
| Open | $0.43 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $0.48 | ||||
| Day Low | $0.43 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 2,643,491 | ||||
- VivoSim makes first commercial sales in China for NAMkind testing
- VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
- Form 8-K VivoSim Labs, INC. For: Jul 16
- VivoSim Labs prices $4M private placement at $0.85 per share
- VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
- Three Biotechs Deliver Catalysts to Watch
- VivoSim receives $5M milestone payment from Eli Lilly
- VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
- Form 10-K VivoSim Labs, INC. For: Mar 31
- Form NT 10-K VivoSim Labs, INC. For: Mar 31
Entities mentioned with VIVS
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- S1 | View Related Stories »
- Barclays | View Related Stories »
- BofA/Merrill Lynch | View Related Stories »
- 13G | View Related Stories »
- Show More...
